An update on optic neuritis

被引:0
作者
Jessica A. Kraker
John J. Chen
机构
[1] Mayo Clinic Hospital,Department of Ophthalmology
[2] Mayo Clinic Hospital,Department of Neurology
来源
Journal of Neurology | 2023年 / 270卷
关键词
Optic neuritis; Neuro-ophthalmology; Multiple sclerosis; Neuromyelitis optica spectrum disorder; MOG antibody-associated disease; Chronic relapsing inflammatory optic neuropathy;
D O I
暂无
中图分类号
学科分类号
摘要
Optic neuritis (ON) is the most common cause of subacute optic neuropathy in young adults. Although most cases of optic neuritis (ON) are classified as typical, meaning idiopathic or associated with multiple sclerosis, there is a growing understanding of atypical forms of optic neuritis such as antibody mediated aquaporin-4 (AQP4)-IgG neuromyelitis optica spectrum disorder (NMOSD) and the recently described entity, myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD). Differentiating typical ON from atypical ON is important because they have different prognoses and treatments. Findings of atypical ON, including severe vision loss with poor recovery with steroids or steroid dependence, prominent optic disc edema, bilateral vision loss, and childhood or late adult onset, should prompt serologic testing for AQP4-IgG and MOG-IgG. Although the traditional division of typical and atypical ON can be helpful, it should be noted that there can be severe presentations of otherwise typical ON and mild presentations of atypical ON that blur these traditional lines. Rare causes of autoimmune optic neuropathies, such as glial fibrillary acidic protein (GFAP) and collapsin response-mediator protein 5 (CRMP5) autoimmunity also should be considered in patients with bilateral painless optic neuropathy associated with optic disc edema, especially if there are other accompanying suggestive neurologic symptoms/signs. Typical ON usually recovers well without treatment, though recovery may be expedited by steroids. Atypical ON is usually treated with intravenous steroids, and some forms, such as NMOSD, often require plasma exchange for acute attacks and long-term immunosuppressive therapy to prevent relapses. Since treatment is tailored to the cause of the ON, elucidating the etiology of the ON is of the utmost importance.
引用
收藏
页码:5113 / 5126
页数:13
相关论文
共 1724 条
[91]  
van den Noort S(2023)Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: international MOGAD Panel proposed criteria Lancet Neurol 22 265-3577
[92]  
Weinshenker BY(2020)Brainstem and cerebellar involvement in MOG-IgG-associated disorder versus aquaporin-4-IgG and MS J Neurol Neurosurg Psychiatry 15 752-111
[93]  
Wolinsky JS(2019)Myelin oligodendrocyte glycoprotein antibodies in neurological disease Nat Rev Neurol 89 845-525
[94]  
Thompson AJ(2017)Prognostic relevance of MOG antibodies in children with an acquired demyelinating syndrome Neurology 22 297-26
[95]  
Banwell BL(2016)Clinical and MRI phenotype of children with MOG antibodies Mult Scler 87 2088-284
[96]  
Barkhof F(2016)Antibodies to MOG and AQP4 in children with neuromyelitis optica and limited forms of the disease J Neurol Neurosurg Psychiatry 86 811-1133
[97]  
Carroll WM(2015)Clinical and neuroradiological differences of paediatric acute disseminating encephalomyelitis with and without antibodies to the myelin oligodendrocyte glycoprotein J Neurol Neurosurg Psychiatry 69 1052-1307
[98]  
Coetzee T(2012)Anti-myelin oligodendrocyte glycoprotein antibodies in pediatric patients with optic neuritis Arch Neurol 265 82-309
[99]  
Comi G(2018)MRI of the first event in pediatric acquired demyelinating syndromes with antibodies to myelin oligodendrocyte glycoprotein J Neurol 93 3565-146
[100]  
Correale J(2023)Cerebral cortical encephalitis in myelin oligodendrocyte glycoprotein antibody-associated disease Ann Neurol 49 109-281